Cited by 190Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

Open access

Lagmay, Joanne P., Krailo, Mark D., Dang, Ha, Kim, AeRang, Hawkins, Douglas S., Beaty, Orren, Widemann, Brigitte C., Zwerdling, Theodore, Bomgaars, Lisa, Langevin, Anne-Marie, Grier, Holcombe E., Weigel, Brenda, Blaney, Susan M., Gorlick, Richard, Janeway, Katherine A.·2016·Journal of Clinical Oncology

DOI 10.1200/jco.2015.65.5381PMC PMC5012712

Open this paper in CoChat — free account

Abstract

Purpose: The use of radiographic response as the primary end point in phase II osteosarcoma trials may limit optimal detection of treatment response because of the calcified tumor matrix. We performed this study to determine if time to progression could be used as an end point for subsequent studies. Patients and Methods: We performed a retrospective analysis of outcome for patients with recurrent/refractory osteosarcoma enrolled in one of seven phase II trials conducted by the Children’s Oncology Group and predecessor groups from 1997 to 2007. All trials used RECIST or WHO radiographic response criteria and the primary end point of response rate. The following potential prognostic factors—age, trial, number of prior chemotherapy regimens, sex, and race/ethnicity—were evaluated for their impact on event-free survival (EFS). We used data from a phase II study (AOST0221) of patients with osteosarcoma who were given inhaled granulocyte-macrophage colony-stimulating factor with first pulmonary recurrence who had an EFS as well as biologic end point to determine the historical disease control rate for patients with fully resected disease. Results: In each included trial, the drugs tested were determined to be inactive on the basis of radiographic response rates. The EFS for 96 patients with osteosarcoma and measurable disease was 12% at 4 months (95% CI, 6% to 19%). There was no significant difference in EFS across trials according to number of prior treatment regimens or patient age, sex, and ethnicity. The 12-month EFS for the 42 evaluable patients enrolled in AOST0221 was 20% (95% CI, 10% to 34%). Conclusion: The EFS was uniformly poor for children with recurrent/refractory osteosarcoma in these single-arm phase II trials. We have now constructed baseline EFS outcomes that can be used as a comparison for future phase II trials for recurrent osteosarcoma.

Integrity signals

Registry

Crossref · 10.1200/jco.2015.65.5381

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Statistical Analysis of Failure Time Data
Klein, J. P., Kalbfleisch, J. D., & Prentice, R. L. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,248
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Womer, R. B., West, D. C., Krailo, M., Dickman, P. S., Pawel, B., Grier, H. E., Marcus, K. J., Sailer, S. L., Healey, J. H., Dormans, J. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5703 · Cited by 761
Self-citation
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Self-citation
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Self-citation
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
Korn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 704

Show all 33 references

Sorted by citations

Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Self-citation
Current and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. B., Lewis, V. O., & Gorlick, R. G. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 691
Self-citation
New Horizons in the Treatment of Osteosarcoma
Meltzer, P. S., & Helman, L. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2103423 · Cited by 672
Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Self-citation
Osteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J., & Davis, L. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 477
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E., Chevreau, C., Duffaud, F., Entz-Werlé, N., Saada, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30825-3 · Cited by 326
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30742-3 · Cited by 331
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 300
Future directions in the treatment of osteosarcoma
Bishop, M. W., Janeway, K. A., & Gorlick, R. G. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000298 · Cited by 266
Self-citation
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02374 · Cited by 268
Improving human cancer therapy through the evaluation of pet dogs
LeBlanc, A. K., & Mazcko, C. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0297-3 · Cited by 207
Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma
Li, B., Zhou, P., Xu, K., Chen, T., Jiao, J., Wei, H., Yang, X., Xu, W., Wan, W., & Xiao, J. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.33787 · Cited by 196
Advances in the management of osteosarcoma
Bielack, S., Hecker‐Nolting, S., Blattmann, C., & Kager, L. (2016) · F1000Research · doi:10.12688/f1000research.9465.1 · Cited by 152
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 144
The functional roles of the circRNA/Wnt axis in cancer
Xue, C., Li, G., Zheng, Q., Gu, X., Bao, Z., Lü, J., & Li, L. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01582-0 · Cited by 145
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Harris, M. A., & Hawkins, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073817 · Cited by 148
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes
Ligon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group
Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127
Self-citation
Biodegradable NIR‐II Pseudo Conjugate Polymeric Nanoparticles Amplify Photodynamic Immunotherapy via Alleviation of Tumor Hypoxia and Tumor‐Associated Macrophage Reprogramming
Wan, J., Zhang, X., Tang, D., Liu, T., & Xiao, H. (2023) · Advanced Materials · doi:10.1002/adma.202209799 · Cited by 122
Anti-angiogenesis target therapy for advanced osteosarcoma
Xie, L., Ji, T., & Guo, W. (2017) · Oncology Reports · doi:10.3892/or.2017.5735 · Cited by 119
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
Hegde, M. G., Navai, S. A., DeRenzo, C. C., Joseph, S. K., Sanber, K. S., Wu, M., Gad, A. Z., Janeway, K. A., Campbell, M., Mullikin, D. R., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00749-6 · Cited by 114
Self-citation
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
Gaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, F., Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00387-9 · Cited by 89
Monocytes, Macrophages, and Osteoclasts in Osteosarcoma
Kelleher, F. C., & O’Sullivan, H. (2017) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2016.0078 · Cited by 84
MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma
Cao, L., Wang, J., & Wang, Q. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.008 · Cited by 79
Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group
Kopp, L. M., Malempati, S., Krailo, M., Gao, Y., Buxton, A. B., Weigel, B. J., Hawthorne, T. R., Crowley, E. M., Moscow, J. A., Reid, J. M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.015 · Cited by 79
Self-citation
Current Status and Prospects of Targeted Therapy for Osteosarcoma
Hu, Z., Wen, S., Huo, Z., Wang, Q., Zhao, J., Wang, Z., Chen, Y., Zhang, L., Zhou, F., Guo, Z., et al. (2022) · Cells · doi:10.3390/cells11213507 · Cited by 78
Phase-II trials in osteosarcoma recurrences: A systematic review of past experience
Omer, N., Deley, M. L., Piperno-Neumann, S., Marec‐Bérard, P., Italiano, A., Corradini, N., Bellera, C. A., Brugières, L., & Gaspar, N. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.005 · Cited by 71
Guideline for Limb‐Salvage Treatment of Osteosarcoma
Xu, M., Wang, Z., Yu, X., Lin, J., & Hu, Y. (2020) · Orthopaedic Surgery · doi:10.1111/os.12702 · Cited by 70
Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
Nguyen, P., Okeke, E., Clay, M. R., Haydar, D., Justice, J., O'Reilly, C., Pruett‐Miller, S. M., Papizan, J. B., Moore, J., Zhou, S., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.018 · Cited by 66
Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma
Guenther, L. M., Rowe, R. G., Acharya, P. T., Swenson, D. W., Meyer, S. C., Clinton, C. M., Guo, D., Sridharan, M., London, W. B., Grier, H. E., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26896 · Cited by 66
Self-citation
Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
Xie, L., Guo, W., Wang, Y., Yan, T., Ji, T., & Xu, J. H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4303-z · Cited by 64
Targeting the VEGF Pathway in Osteosarcoma
Assi, T., Watson, S., Samra, B., Rassy, E., Cesne, A. L., Italiano, A., & Mir, O. (2021) · Cells · doi:10.3390/cells10051240 · Cited by 62
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆
Gaspar, N., Campbell-Hewson, Q., Gallego Melcon, S., Locatelli, F., Venkatramani, R., Hecker-Nolting, S., Gambart, M., Bautista, F., Thebaud, E., Aerts, I., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100250 · Cited by 59
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Gazouli, I., Kyriazoglou, A., Kotsantis, I., Anastasiou, M., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Kontogeorgakos, V., et al. (2021) · Cancers · doi:10.3390/cancers13081757 · Cited by 63
Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells
Sauer, S. J., Reed, D. R., Ihnat, M. A., Hurst, R. E., Warshawsky, D., & Barkan, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659963 · Cited by 59
Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
LeBlanc, A. K., Mazcko, C. N., Cherukuri, A., Berger, E. P., Kisseberth, W. C., Brown, M. E., Lana, S. E., Weishaar, K. M., Flesner, B. K., Bryan, J. N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0315 · Cited by 55
Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas
Nakano, K., & Takahashi, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030739 · Cited by 53
Current questions in bone sarcomas
Strauss, S. J., & Whelan, J. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000456 · Cited by 49
GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.
(2020) · PubMed Central · Cited by 47
Self-citation
Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans
Mannheimer, J., Tawa, G. J., Gerhold, D. L., Braisted, J. C., Sayers, C. M., McEachron, T. A., Meltzer, P. S., Mazcko, C. N., Beck, J. A., & LeBlanc, A. K. (2023) · Communications Biology · doi:10.1038/s42003-023-05208-z · Cited by 52
Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models
Talbot, L. J., Chabot, A., Ross, A. B., Beckett, A., Nguyen, P., Fleming, A. M., Chockley, P. J., Sheppard, H., Wang, J., Gottschalk, S. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3298 · Cited by 48
PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy
Xu, J. H., Xie, L., & Guo, W. (2018) · Clinical Sarcoma Research · doi:10.1186/s13569-018-0102-1 · Cited by 41
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group
Hingorani, P., Krailo, M., Buxton, A. B., Hutson, P. R., Sondel, P. M., Diccianni, M. B., Yu, A. L.-T., Morris, C. D., Womer, R. B., Crompton, B. D., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.035 · Cited by 42
Self-citation
The antitumor antibiotic rebeccamycin—challenges and advanced approaches in production processes
Pommerehne, K., Walisko, J., Ebersbach, A. T., & Krull, R. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09741-y · Cited by 41
The Notch Pathway Promotes Osteosarcoma Progression through Activation of Ephrin Reverse Signaling
Yu, L., Xia, K., Gao, T., Chen, J., Zhang, Z., Sun, X., Simões, B. M., Eyre, R., Fan, Z., Guo, W., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0493 · Cited by 39
Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
Liu, Z., Gao, S., Zhu, L., Wang, J., Zhang, P., Li, P., Zhang, F., & Yao, W. (2021) · Cancer Medicine · doi:10.1002/cam4.4286 · Cited by 36
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells
Yankelevich, M., Thakur, A. B., Modak, S. I., Chu, R. L., Taub, J. W., Martin, A., Schalk, D. L., Schienschang, A., Whitaker, S. A., Rea, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008744 · Cited by 36
Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
Koo, J., Hayashi, M., Verneris, M. R., & Lee‐Sherick, A. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581107 · Cited by 34
Metabolism of Reactive Oxygen Species in Osteosarcoma and Potential Treatment Applications
Sun, W., Wang, B., Qu, X., Zheng, B., Huang, W., Sun, Z., Wang, C., & Chen, Y. (2019) · Cells · doi:10.3390/cells9010087 · Cited by 32
Role of TKI for Metastatic Osteogenic Sarcoma
Duffaud, F. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00760-w · Cited by 30
Advances in the Treatment of Pediatric Bone Sarcomas
Grohar, P. J., Janeway, K. A., Maese, L. D., & Schiffman, J. D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175378 · Cited by 30
Self-citation
European standard clinical practice recommendations for children and adolescents with primary and recurrent osteosarcoma
van Ewijk, R., Herold, N., Baecklund, F., Baumhoer, D., Boye, K., Gaspar, N., Harrabi, S., Haveman, L., Hecker‐Nolting, S., Hiemcke‐Jiwa, L. S., et al. (2023) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2023.100029 · Cited by 33
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group
Isakoff, M. S., Goldsby, R. E., Villaluna, D., Krailo, M., Hingorani, P., Collier, A. B., Morris, C. D., Kolb, E. A., Doski, J. J., Womer, R. B., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27524 · Cited by 29
Self-citation
What is the best clinical approach to recurrent/refractory osteosarcoma?
Meazza, C., Bastoni, S., & Scanagatta, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760848 · Cited by 28
Pazopanib for second recurrence of osteosarcoma in pediatric patients
Umeda, K., Kato, I., Saida, S., Okamoto, T., & Adachi, S. (2017) · Pediatrics International · doi:10.1111/ped.13307 · Cited by 28
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial
Palmerini, E., Lopez Pousa, A., Grignani, G., Redondo, A., Hindi, N., Provenzano, S., Sebio, A., Lopez Martin, J. A., Valverde, C., Martinez Trufero, J., et al. (2025) · Cancer · doi:10.1002/cncr.35628 · Cited by 29
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4381 · Cited by 28
Self-citation
A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma
Marec‐Bérard, P., Dalban, C., Gaspar, N., Brugières, L., Gentet, J., Lervat, C., Corradini, N., Castex, M., Schmitt, C., Pacquement, H., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.007 · Cited by 27
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma
Just, M. A., Mater, D. V., & Wagner, L. M. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29084 · Cited by 27
Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma
Zhou, P., Li, Y., Li, B., Zhang, M., Xu, C., Liu, F.-R., Bian, L., Liu, Y., Yao, Y., & Li, D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1467677 · Cited by 27
Sarcoma as a Model for Adolescent and Young Adult Care
Reed, D. R., Naghavi, A. O., & Binitie, O. T. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00684 · Cited by 27
Challenges of Systemic Therapy Investigations for Bone Sarcomas
Nakano, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073540 · Cited by 25
Re-calculating! Navigating through the osteosarcoma treatment roadblock
McGuire, J., Utset‐Ward, T. J., Reed, D. R., & Lynch, C. C. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.004 · Cited by 26
Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center
Evenhuis, R. E., Acem, I., Rueten‐Budde, A. J., Karis, D. S. A., Fiocco, M. F., Dorleijn, D. M. J., Speetjens, F. M., Anninga, J., Gelderblom, H. A. J., & van de Sande, M. A. J. (2021) · Cancers · doi:10.3390/cancers13030486 · Cited by 24
223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy
Anderson, P. M., Scott, J. G., Parsai, S., Zahler, S. G., Worley, S. E., Shrikanthan, S., Subbiah, V., & Murphy, E. S. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000635 · Cited by 24
Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials
Akshintala, S., Mallory, N. C., Lu, Y., Ballman, K. V., Schuetze, S. M., Chugh, R. K., Maki, R. G., Reinke, D. K., Widemann, B. C., & Kim, A. (2023) · The Oncologist · doi:10.1093/oncolo/oyac272 · Cited by 24
Self-citation
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas
Pearson, A. D., Gaspar, N., Janeway, K., Campbell-Hewson, Q., Lawlor, E. R., Copland, C., Karres, D., Norga, K., Benzaghou, F., Weiner, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.008 · Cited by 22
Self-citation
Patterns of metastatic progression and association with clinical outcomes in canine osteosarcoma: A necropsy study of 83 dogs
Silver, K. I., Patkar, S., Mazcko, C. N., Berger, E. P., Beck, J. A., & LeBlanc, A. K. (2023) · Veterinary and Comparative Oncology · doi:10.1111/vco.12927 · Cited by 22
Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?
Thébault, É., Piperno-Neumann, S., Tran, D., Pacquement, H., Marec‐Bérard, P., Lervat, C., Castex, M., Cleirec, M., Bompas, E., Vannier, J., et al. (2021) · Cancers · doi:10.3390/cancers13071683 · Cited by 22
Systematic review of phase‐I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research
Felix, A., Berlanga, P., Toulmonde, M., Landman‐Parker, J., Dumont, S., Vassal, G., Deley, M. L., & Gaspar, N. (2021) · Cancer Medicine · doi:10.1002/cam4.3712 · Cited by 22
Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial
Tang, L., Niu, X., Wang, Z., Cai, Q., Tu, C., Fan, Z., & Yao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811687 · Cited by 21
Recent advances in understanding osteosarcoma and emerging therapies
Gaspar, N., Costa, M. E. M. D., Fromigué, O., Droit, R., Berlanga, P., & Marchais, A. (2020) · Faculty Reviews · doi:10.12703/r/9-18 · Cited by 22
Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
Xie, L., Xu, J., Sun, X., Li, X., Liu, K., Liang, X., Zhou, Z., Zhuang, H., Sun, K., Wu, Y., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12813 · Cited by 19
Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma
Wen, X., Pan, Q., Xu, B.-S., Xiao, W., Weng, D., Zhao, J., Xu, H.-R., Huang, Z., Niu, X., & Zhang, X. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04371-6 · Cited by 20
Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers
Deyell, R. J., Shen, Y., Titmuss, E., Dixon, K., Williamson, L. M., Pleasance, E., Nelson, J., Abbasi, S., Krzywinski, M. I., Armstrong, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48363-5 · Cited by 24
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
Kairemo, K., ROHREN, E. M., Anderson, P. M., RAVIZZINI, G. C., Rao, A., Macapinlac, H. A., & Subbiah, V. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000439 · Cited by 20
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas
Schulte, B., Mohindra, N., Milhem, M., Attia, S., Robinson, S., Monga, V., Hirbe, A. C., Oppelt, P., Charlson, J., Helenowski, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01448-0 · Cited by 19
Antiangiogenic agents combined with systemic chemotherapy in refractory osteosarcoma
Rutkowski, P. L. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00422-8 · Cited by 19
Children's Oncology Group's 2023 blueprint for research: Bone tumors
Reed, D. R., Grohar, P. J., Rubin, E. M., Binitie, O. T., Krailo, M., Davis, J. L., DuBois, S. G., & Janeway, K. A. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30583 · Cited by 21
Self-citation
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?
van Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19
Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights
Zhang, Y., Jiang, S., Lv, J., Feng, W., Yu, Y., & Zhao, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584450 · Cited by 22
Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial
Koonrungsesomboon, N., Ngamphaiboon, N., Townamchai, N., Teeyakasem, P., Charoentum, C., Charoenkwan, P., Natesirinilkul, R., Sathitsamitphong, L., Ativitavas, T., Chaiyawat, P., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06751-2 · Cited by 18
Integrating Radiogenomics and Machine Learning in Musculoskeletal Oncology Care
Kumar, R. R., Sporn, K., Khanna, A., Paladugu, P., Gowda, C., Ngo, A., Jagadeesan, R., Zaman, N., & Tavakkoli, A. (2025) · Diagnostics · doi:10.3390/diagnostics15111377 · Cited by 21
Evaluating and Predicting the Probability of Death in Patients with Non-Metastatic Osteosarcoma: A Population-Based Study
Huang, R., Xian, S., Shi, T., Yan, P., Hu, P., Yin, H., Meng, T., & Huang, Z. (2019) · Medical Science Monitor · doi:10.12659/msm.915418 · Cited by 17
Sex differences in osteosarcoma survival across the age spectrum: A National Cancer Database analysis (2004–2016)
Williams, L. A., Barragan, S., Lu, Z., Weigel, B. J., & Spector, L. G. (2024) · Cancer Epidemiology · doi:10.1016/j.canep.2024.102565 · Cited by 17
Self-citation
Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
Kokkali, S., Kyriazoglou, A. I., Mangou, E., Economopoulou, P., Panousieris, M., Psyrri, A. K., Ardavanis, A. S., Vassos, N., & Boukovinas, I. P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031119 · Cited by 17
Comprehensive analysis of angiogenesis pattern and related immune landscape for individual treatment in osteosarcoma
Liao, Z., Li, M., Wen, G., Wang, K., Yao, D., Chen, E., Liang, Y., Xing, T., Su, K., Liang, C., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00415-7 · Cited by 17
Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement
Green, D., van Ewijk, R., Tirtei, E., Andreou, D., Baecklund, F., Baumhoer, D., Bielack, S., Botchu, R., Boye, K., Brennan, B. M. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0101 · Cited by 20
miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib
Wang, L., En, H., Yang, L., Zhang, Y., Sun, B., & Gao, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s215145 · Cited by 17
The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis
Liu, J.-Y., Zhu, B., Wang, Y., & Sun, X. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01644-7 · Cited by 17
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force
Whittle, S. B., Offer, K., Roberts, R. D., LeBlanc, A. K., London, C. A., Majzner, R. G., Huang, A. Y.-C., Houghton, P. J., Sweet-Cordero, A., Grohar, P. J., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29188 · Cited by 18
Self-citation
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)
Barnes, D., Dutton, P., Bruland, Ø. S., Gelderblom, H. A. J., Faleti, A., Bühnemann, C., van Maldegem, A. M., Johnson, H., Poulton, L., Love, S., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09697-9 · Cited by 16
Osteosarcoma
Bishop, M. W. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.04.005 · Cited by 16
Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming
Yang, Y., Peng, Z., Flores, E. R., & Kleinerman, E. S. (2022) · Cancers · doi:10.3390/cancers14174310 · Cited by 15
Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma
Perret, A., Dômont, J., Chamseddine, A. N., Dumont, S., Verret, B., Briand, S., Court, C., Lazure, T., Adam, J., Ngo, C., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3610 · Cited by 14
Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas
Wood, G. E., Graves, L. A., Rubin, E. M., Reed, D. R., Riedel, R. F., & Strauss, S. J. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390306 · Cited by 16
Current treatment landscape and emerging management options for extremity sarcoma
Turkar, S. (2018) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_9_19 · Cited by 13
Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy
Xie, L., Chen, C., Liang, X., Xu, J. H., Sun, X., Sun, K., Yang, R., Tang, X., & Guo, W. (2022) · Orthopaedic Surgery · doi:10.1111/os.13620 · Cited by 13
Assembly of a biomimetic copper-based nanocomplex for alleviating hypoxia to enhance cuproptosis against osteosarcoma and lung metastasis
Wu, J., Hao, X., Qi, L., Xu, W., Yin, C., Tang, Y., Sun, P., Liao, D., Hu, X.-B., Tang, T., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.12.049 · Cited by 13
Pathologic fracture in childhood and adolescent osteosarcoma: A single-institution experience
Haynes, L., Kaste, S. C., Ness, K. K., Wu, J., Ortega-Laureano, L., Bishop, M. W., Neel, M. D., Rao, B., & Fernández‐Pineda, I. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26290 · Cited by 13

Authors: Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O., Widemann, B. C., Zwerdling, T., Bomgaars, L., Langevin, A.-M., Grier, H. E., Weigel, B., Blaney, S. M., Gorlick, R., & Janeway, K. A.
Affiliations: University of Southern California (US)
ORCID: Lagmay, Joanne P.
Krailo, Mark D.
Dang, Ha
Kim, AeRang
Hawkins, Douglas S.
Widemann, Brigitte C.
Bomgaars, Lisa
Langevin, Anne-Marie
Grier, Holcombe E.
Weigel, Brenda
Blaney, Susan M.
Gorlick, Richard
Janeway, Katherine A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2016-09-01
Volume: 34
Issue: 25
Pages: 3031-3038
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2015.65.5381
PMC: PMC5012712
OpenAlex: W2473766695
Cited by: 190
References: 33
Citations by year: 2026: 11 · 2025: 20 · 2024: 23 · 2023: 25 · 2022: 19 · 2021: 27 · 2020: 19 · 2019: 16 · 2018: 14 · 2017: 10 · 2016: 5
FWCI: 13.42
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Children’s Oncology Group (U10 CA180886, U10 CA180899)
National Cancer Institute (U10 CA-98413, U10-CA98543, U10CA098413, U10CA180899, U10CA180886, U10CA098543)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords: recurrent osteosarcoma, event-free survival, time to progression, prognostic factors, pediatric oncology, GM-CSF
MeSH terms: Adolescent, Bone Neoplasms, Child, Female, Humans, Male, Neoplasm Recurrence, Local, Retrospective Studies, Osteosarcoma, Treatment Outcome, Clinical Trials, Phase II as Topic, Disease-Free Survival, Endpoint Determination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks